Press

25 Aug Her Majesty the Queen Sofia of Spain pays a private visit to the research group lead by Dr escriba and Dr. Busquets at the UIB

Posted at 13:49h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Her Majesty the Queen Sofia of Spain has made today a private visit to the Laboratory of Molecular and Cellular Biomedicine of the University of the Balearic Islands. The research group, led by...

16 Jun Prof. G.L. Nicolson and Prof. R.M. Epand join Laminar Pharma’s SAB

Posted at 13:50h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Laminar Pharma Scientific Advisory Board (SAB) has held a meeting today in Madrid were a group of leading scientist had discussed the molecular basis and mechanism of action of the novel MLT-based LP226A1,...

18 Dec Laminar Pharma galardonada con el Premio Onda Cero Mallorca de Ciencia e Investigación 2013

Posted at 13:54h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Laminar Pharma, empresa co-fundadora del Cluster Biotecnológico y Biomédico de las Illes Balears (BIOIB), recibe el Premio Onda Cero Mallorca de Ciencia e Investigación por sus avances científicos en el campo biomédico, especialmente...

10 Dec Laminar Pharma awarded as one of the best European biotech projects at the EVC 2013

Posted at 13:58h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]-> Laminar Pharma was selected as one of the 8 best European projects in the Health Care space by a prestigious panel of 28 directives of pharmaceutical companies and Venture Capital Funds specialized...

15 May Laminar Pharma presented yesterday its cancer program with 2OHOA at Biotrinity 2013 and announced the start of the first oncology clinical study with this novel lipid regulator.

Posted at 14:00h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]After obtaining all required regulatory authorizations in the UK for the clinical study MIN-001-1203, Laminar Pharma confirmed the activation of the first site in Sutton, Surrey (UK), which will be recruiting participants from today....

13 Mar Laminar Pharma’s CEO, Vicenç Tur, presented yesterday the innovative R&D program in oncology with 2OHOA at the Bio-Europe Spring 2013 event in Barcelona

Posted at 14:02h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]2OHOA is a new class of lipid regulator, multi-target anticancer drug for tumors with sphingomyelin metabolism alterations. It activates sphingomyelin synthase (SMS), a new and powerful potential anticancer drug target, which results in a specific...

04 Mar Laminar Pharma went through the semi final of the European Venture Contest and will present in Berlin at the final session of the EVC Healthcare

Posted at 14:07h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]In the semi final session of the European Venture Contest, held on the 24th of October in Aarhus (Denmark), Laminar Pharma was one of the 6 projects selected by a prestigious panel of...

02 Mar EMA’s COMP grants Orphan Medicinal Product Designation to Laminar Pharma’s 2OHOA for the treatment of glioma.

Posted at 14:04h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued in September 2011 a positive opinion recommending orphan medicinal product (Orphan Drug, OD) designation for 2OHOA for the treatment of glioma. 2OHOA is a novel investigational...